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Abstract. Targeted theranosis (diagnosis combined to 
therapy) strategies are intended to improve cancer 
treatment efficacy while decreasing side effects. 
Nanovectors of hybrid (organic/inorganic) structure 
allow to combine multiple physical and biological 
functions and thus are being developed as promising 
contrast agents for multimodal diagnosis and drug 
nanocarriers for therapy of cancers. We present here 
three types of theranostic nanovectors our group 
develops, all based on combination of magnetic and 
optical properties with biological targeting and 
anticancer activity. Development of these nanovectors is 
being made in the frame of a multidisciplinary research, 
including biotechnology, chemical synthesis, 
pharmaceutical technology, physico-chemical and 
biological analysis in vitro and in vivo. The rational 
design of our nanovectors has been confirmed by 
complementary techniques as leading to promising 
biocompatibility and theranostic potential.  
 
Index terms - Biomedical sensors, Nano medicine 
 
I. INTRODUCTION 
 
Diagnosis of cancers and the image-monitored treatment 
are the basis of the so called theranostic strategies which 
are being actively developed. For more efficient and 
accurate diagnosis, magnetic resonance imaging (MRI), 
computed tomography (CT), ultrasound (US) and nuclear 
imaging of positron emission tomography (PET) [1] are 
being combined in multi-modal approaches [2]. Indeed, 
spatially resolved 3D detection of tumors with MRI can be 
advantageously combined with endoscopic detection of 
superficial tumors by means of optical probes operating in 
the tissue optical window in Very Near InfraRed (VNIR). 
Sensitive real-time VNIR detection of small tumors can be 
achieved using fluorescence emission and/or Raman 
scattering, in particular if one used surface-enhanced 
resonance Raman scattering (SERRS) [3]. SERS is as 
sensitive as fluorescence but provides even higher 
molecular specificity due to a unique vibrational signature 
of molecules. Moreover, SERS allows simultaneous 
(multiplex) detection of several signals within complex 
biological environments [4].  
Hybrid, organic-inorganic nanostructures can be used for 
multimodal diagnosis since they allow combining multiple 
nanomaterials (magnetic NPs, plasmonic NPs, drugs, 
biological targeting ligands) and functionalities [5]. This is 
the case of nanovectors we developed for bi-modal (MRI-
fluorescence) and tri-modal (MRI-SERRS-fluorescence) 
detection of cancer cells as described below.  
The core of our nanovectors is composed of 
superparamagnetic iron oxide nanoparticles (SPIONs) 
alone or combined with plasmonic AgNPs. The SPIONs 
generate a negative contrast on T2*-weighted MRI and are 
well known to improve the in vivo cancer detection [1]. 
The plasmonic surface of AgNPs provides enhanced 
Raman response of adsorbed molecules. For optical 
detection, we labelled the nanovectors with VNIR 
fluorophores and/or to Raman reporter molecules attached 
to the inorganic cores and coated them with biocompatible 
polymers. The biological ligands like scFv antibody 
fragments of Herceptin® and folic acid molecules are 
bound to the external polymeric surface of the nanovectors. 
These ligands enhance the specificity and the efficiency of 
the vector delivery to HER-2 overexpressing breast cancers 
which are the most aggressive breast tumors. Therapeutic 
agents like chemotherapy drugs and siRNA molecules are 
also hidden within the polymeric shell of the nanovectors. 
This structural organization insures the drug/label 
protection and good biocompatibility of the nanovectors, 
and corresponds to the rational design strategy.  
 
II. RESULTS 
a. Covalently assembled magnetic 
nanovectors of chemotherapy agent 
We generate our covalently assembled nanovectors via 
silane-mediated binding of native or ligand-modified PEG 
chains and fluorophores to the SPION surface [6]. For this, 
one-pot synthesis protocols proposed by our team have the 
advantage of reducing the number of intermediate steps. To 
load these nanovectors with anticancer drug doxorubicin, 
we developed an experimental approach using pre-formed 
chelate doxorubicin-Fe2+ [7]. The interest of this approach 
consists in the accelerated drug release in acidic 
environment as it is the case in tumors and in cell 
lysosomes. Such nanovectors of doxorubicin have been 
shown to be stealthy [8] and to possess a significant MRI-
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fluorescent response, anticancer activity in vitro [7] and in 
vivo [9], and reduced hematotoxicity. 
 From recently, we are working to improve the 
cancer targeting efficiency of our nanovectors by 
decorating them with a single-chain variable fragment 
(scFv, molecular weight ca 27-28 kDa) targeting HER-2. 
This strategy has several advantages over whole 
antibodies: (i) the scFv are one-fifth the size of whole IgG 
antibodies (thus, nanoplatforms functionalised with scFv 
are much smaller) and they retain full antigen bonding 
capacity; (ii) unlike whole antibodies, scFv do not contain 
the Fc constant domain and therefore are not able to trigger 
potentially harmful immune responses.  
  
b. Electrostatically assembled magnetic 
nanovectors of siRNA 
Short interfering RNAs (siRNA) are a promising tool to 
treat various human diseases, including cancer. The siRNA 
act via the RNA interference (RNAi) mechanism. 
However, the systemic administration of siRNAs does not 
allow to attain efficiently the site of action. To overcome 
this difficulty, we develop magnetic siRNA nanovectors 
(MSNs) based on SPIONs coated with siRNA and chitosan 
polymer via layer-by layer electrostatic deposition [10]. In 
addition to protecting siRNAs, chitosan is intended to 
enhance the efficacy of the MSNs transfection to cancer 
cells. To improve the formulation and optimize the 
component quantities, we applied experimental design 
strategy, respectively a Box-Behnken and a Plackett-
Burman design [10]. The method provides surface plots 
helpful to optimize and predict the component quantities of 
the MSNs regarding their hydrodynamic diameter (DH). 
The results show that the most influent parameter was the 
order of the components incorporation. The model 
equations allowed to obtain MSNs with DH smaller than 
100 nm which was desired for their systemic 
administration. 
 
c. Electrostatically assembled magneto-
plasmonic nanoprobes 
Controlled electrostatic assembly of SPIONs, AgNPs, nile 
blue (NB) dye and chitosan (Chi) polymer has been used 
to obtain stable magneto-plasmonic clusters (AgION-Chi) 
able to act as MRI-SERRS-active nanoprobes. The interest 
of the AgION-Chi nanoprobes is in that they are: (i) very 
rapid and easy to produce without using neither toxic 
reagents nor conjugation chemistry; (ii) readily 
biodegradable due to their electrostatic assembly; (iii)   
colloidally and spectrally stable for nearly one month. The 
nanoprobes allowed triple fluorescence-SERRS-MRI 
detection of HeLa cancer cells.  
 
III. DISCUSSION – CONCLUSION 
Rationally designed, the nanovectors described here show 
a good compromise between their physico-chemical 
characteristics (size ca. 100 nm, nearly neutral surface 
charge, long-term colloidal stability, sufficient optical and 
magnetic response) and biological properties 
(biocompatibility in vitro and in vivo, ability to recognize 
cancer cells and to deliver drugs and/or siRNA). 
These nanovectors are theranostic and make possible a 
complementary use of the spatially resolved in vivo 
analysis by MRI with the real time multiplex optical 
sensing by means of VNIR probing. This is expected to 
provide more efficient and flexible solution for cancer 
detection, localization/characterization and therapy. 
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